IMPACT OF CHRONIC THROMBOCYTOPENIA ON CLINICAL OUTCOMES AFTER TAVR: INSIGHTS FROM THE BRAVO-3 RANDOMIZED TRIAL
Daniel Feldman(Cardiovascular Institute of the South), George Dangas(Mount Sinai Hospital), Christian Hengstenberg(Medical University of Vienna), Davide Cao(Cardiovascular Institute of the South), Roberto Violini(IRCCS San Camillo Hospital), Samantha Sartori(Icahn School of Medicine at Mount Sinai), Carlo Andrea Pivato(Cardiovascular Institute of the South), Roxana Mehran(Mount Sinai Hospital), Raban Jeger(Triemli Hospital), Anastasios Roumeliotis(Cardiovascular Institute of the South), Mohan Satish(Cardiovascular Institute of the South), Davis Jones(Cardiovascular Institute of the South), Victor Razuk(Mount Sinai Hospital), Anton Camaj(Columbia University Irving Medical Center), Zhongie Zhang(Cardiovascular Institute of the South), Johny Nicolas(Cardiovascular Institute of the South), Mauro Chiarito(Humanitas University), Markus Ferrari(Helios Dr. Horst Schmidt Kliniken Wiesbaden), Frans Beerkens(Icahn School of Medicine at Mount Sinai), David V. Power(Cardiovascular Institute of the South)
Cited by 0
Related Papers
Clinical End Points in Coronary Stent Trials
|Circulation|2007|5.4k
From Vulnerable Plaque to Vulnerable Patient
|Circulation|2003|2.7k
From Vulnerable Plaque to Vulnerable Patient
|Circulation|2003|2.3k
Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease
|New England Journal of Medicine|2016|1.5k